The evaluation of apomorphine for the treatment of erectile dysfunction

被引:10
作者
Mohee, Amar [1 ]
Bretsztajn, Laure [1 ]
Eardley, Ian [1 ]
机构
[1] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
关键词
apomorphine; erectile dysfunction; impotence; COMBINED ORAL FORMULATIONS; NERVOUS-SYSTEM AGENTS; COMBINATION THERAPY; DOUBLE-BLIND; CROSS-OVER; PAPAVERINE HYDROCHLORIDE; SUBLINGUAL APOMORPHINE; PHENTOLAMINE MESYLATE; COMPARATIVE EFFICACY; SILDENAFIL CITRATE;
D O I
10.1517/17425255.2012.727797
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Erectile dysfunction (ED) is a common condition affecting men. Apomorphine is one of the oral medications that has been used in the management of ED, though over recent years, its use in the management of ED has dwindled. Areas covered: The authors review the evidence available for the use of apomorphine in the management of ED. A Medline search was performed searching for the articles related to the use of apomorphine in the treatment of ED from 2000 to present. The article reviews the erectogenic properties of apomorphine and evaluates its efficacy, suitability and tolerability in management of patients with ED. Expert opinion: Apomorphine SL is more effective than placebos in treating ED and is generally well tolerated in the sublingual formulation, causing tolerable side effects. Newer nasal-spray formulations provide faster efficacy. Its efficacy in patients with multiple co-morbidities is more limited. However, it is not as effective as PDE5-I in the treatment of ED. Its most significant strength is its safety profile. It may have a niche in the treatment ED in patients who have failed treatment with, or are intolerant to other well-established pharmacological treatment for ED (e.g., PDE5-Is). Apomorphine is not a first-line treatment option for patients with ED, especially as it is no more widely available in the western world.
引用
收藏
页码:1447 / 1453
页数:7
相关论文
共 51 条
[1]  
Apomorphine (TAP holdings), 1999, DRUGS R&D, V2, P415
[2]   The pharmacology and clinical pharmacokinetics of apomorphine SL [J].
Argiolas, A ;
Hedlund, H .
BJU INTERNATIONAL, 2001, 88 :18-21
[3]   ACTIVATION WITH (+/-)N-N-PROPYL-NOR-APOMORPHINE (NPA) OF THE MALE-RAT COPULATORY-BEHAVIOR [J].
BENASSIBENELLI, A ;
FERRARI, F .
EXPERIENTIA, 1979, 35 (05) :645-646
[4]   Peripheral relaxant activity of apomorphine and of a D1 selective receptor agonist on human corpus cavernosum strips [J].
Bianca, RDD ;
Sorrentino, R ;
Roviezzo, F ;
Imbimbo, C ;
Palmieri, A ;
De Dominicis, G ;
Montorsi, F ;
Cirino, G ;
Mirone, V .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2005, 17 (02) :127-133
[5]   ORAL BIOAVAILABILITY OF APOMORPHINE IN THE RAT WITH A PORTACAVAL VENOUS ANASTOMOSIS [J].
CAMPBELL, A ;
KULA, NS ;
JEPPSSON, B ;
BALDESSARINI, RJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1980, 67 (01) :139-142
[6]   Dopamine D1 receptor agonists induce penile erections in rats [J].
D'Aquila, PS ;
Panin, F ;
Cossu, M ;
Peana, AT ;
Serra, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 460 (01) :71-74
[7]   Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction [J].
Dula, E ;
Keating, W ;
Siami, PF ;
Edmonds, A ;
O'Neil, J ;
Buttler, S .
UROLOGY, 2000, 56 (01) :130-135
[8]   Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction [J].
Dula, E ;
Bukofzer, S ;
Perdok, R ;
George, M .
EUROPEAN UROLOGY, 2001, 39 (05) :558-563
[9]   An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction [J].
Eardley, I ;
Wright, P ;
Macdonagh, R ;
Hole, J ;
Edwards, A .
BJU INTERNATIONAL, 2004, 93 (09) :1271-1275
[10]   A UK Multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection [J].
Farrell, DJ ;
Morrissey, I ;
De Rubeis, D ;
Robbins, M ;
Felmingham, D .
JOURNAL OF INFECTION, 2003, 46 (02) :94-100